

# Return on Innovation



Global health R&D delivers for Vermont



US government (USG) investment in global health R&D has delivered

**\$1.2 million** to Vermont research institutions\*

## Vermont's top global health R&D institution by USG funding\*



University of Vermont

## Global health R&D at work in the Green Mountain State



PATH/Miguel Alvarez

The University of Vermont's Vaccine Testing Center is designing a research platform upon which new treatments for cryptosporidiosis can be tested in humans. Cryptosporidiosis, or crypto for short, is an infection caused by *Cryptosporidium*, a single-celled intestinal parasite found in soil, food, and water. Crypto is a leading cause of severe diarrhea in infants and young children in low-income countries. It also causes significant illness and death in immunocompromised individuals. No vaccines exist to treat or prevent the infection and there are limited treatment options. In many parts of the world, crypto is associated with poor childhood nutrition and stunted growth. Past work by the center has focused on how crypto contributes to the vicious cycle of diarrhea, infectious diseases, and malnutrition.


## Neglected diseases in Vermont†

HIV diagnoses	137
Tuberculosis cases	48
Malaria cases	29
Zika cases	26
Dengue cases	19

## Vermont industry in global health R&D

**Mylan:** St. Albans City  
**QuantaSpec:** Burlington, Essex Junction

## Vermont's top areas of global health R&D by USG funding\*



## GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES‡



**89¢** of every dollar

the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

**200K** new US jobs

**\$33 BILLION** in US economic growth.

\*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See [www.ghtcoalition.org](http://www.ghtcoalition.org) for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See [www.ghtcoalition.org](http://www.ghtcoalition.org) for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, Malaria cases 2008-2014, Zika virus disease cases 2015-2017, Dengue virus infection cases 2010-2016.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.